Levofloxacin (Levaquin) Use in Breastfeeding
Levofloxacin can be used during breastfeeding with close infant monitoring, as it is excreted in minimal concentrations in breast milk and poses low risk to the nursing infant.
Evidence-Based Recommendation
The FDA drug label states that levofloxacin is presumed to be excreted in human milk, and recommends weighing the decision to discontinue nursing or the drug based on its importance to the mother 1. However, more recent clinical evidence and guidelines support a more permissive approach.
Key Supporting Data
Fluoroquinolones produce low breast milk concentrations with acceptable safety profiles 2. The 2025 CDC guidelines for tularemia treatment explicitly state that fluoroquinolones "typically produce low concentrations in breast milk and have an acceptable safety profile" in lactating mothers 2.
The 2025 Global Consensus Statement on IBD management provides the most relevant direct evidence: while discussing ciprofloxacin (a closely related fluoroquinolone), it notes that fluoroquinolones have minimal concentrations in breast milk 3. In a study of nursing women receiving 750 mg ciprofloxacin twice daily, peak breast milk concentration was 3.79 mg/L at 2 hours, with very low concentrations of 0.20 mg/L at 12 hours and 0.02 mg/L at 24 hours 3. Very few side effects have been reported in newborns of mothers treated with fluoroquinolones during lactation 3.
Recent pharmacokinetic research on levofloxacin specifically found that the relative infant dose through breastfeeding was only 6-8% of the recommended pediatric dose, with a breastmilk:plasma ratio of 1.46 4. Peak levofloxacin concentration in breast milk was 8.2 mcg/mL at 5 hours after dosing, but infant exposure remained below concentrations studied in pediatric populations 5.
Clinical Implementation
When to Use
- Levofloxacin is considered low risk for nursing mothers when clinically indicated 3
- The 2020 ERS/TSANZ guidelines classify ciprofloxacin (the reference fluoroquinolone) as "possibly safe" during breastfeeding, noting that while most clinicians try to avoid fluoroquinolones, human data suggest low risk 6
Infant Monitoring Protocol
Monitor the breastfed infant for:
- Diarrhea or loose stools
- Candidiasis (oral thrush or diaper rash)
- Poor feeding or drowsiness
- Any signs of gastrointestinal flora disruption 3
Important Caveats
Timing considerations: Peak levofloxacin concentration in breast milk occurs at 5 hours post-dose 5. If feasible, mothers could time breastfeeding to avoid peak milk concentrations, though this is not strictly necessary given the low overall infant exposure.
Alternative antibiotics: While levofloxacin is acceptable, if equally effective alternatives exist that are definitively compatible with breastfeeding (such as amoxicillin or cephalosporins for appropriate infections), those should be considered first 3.
Theoretical concerns vs. actual risk: Historical concerns about fluoroquinolone-associated cartilage damage in developing joints were based on animal studies. Human data have not confirmed this risk at therapeutic exposures through breast milk 6, 7. The actual infant exposure through breast milk is substantially below therapeutic pediatric dosing 4, 5.
Contraindications to Breastfeeding While on Levofloxacin
- Premature infants (increased theoretical risk)
- Infants with known glucose-6-phosphate dehydrogenase deficiency
- Jaundiced neonates in the first weeks of life
The evidence supports continued breastfeeding in most clinical scenarios when levofloxacin is medically necessary for the mother, with appropriate infant monitoring for gastrointestinal effects.